Clinical trials: Hepatitis B Chronic Infection
Chronic Hepatitis B
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B
This randomized study will be conducted in two parts to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931.
- Trial name
- NCT03038113
- Testing
- RO7062931, Immune Modulator
- Where
- 19 sites in Australia, Hong Kong and 5 more
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B Virus Infection
Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection
Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied.
- Trial name
- NCT06544551
- Testing
- Peginterferon Alfacon-2
- Where
- 34 sites in China
- Volunteers
- 336 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis b
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B
CB06-036 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B.
- Trial name
- NCT05828745
- Testing
- CB06-036
- Where
- 2 sites in China, New Zealand
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Chronic Hepatitis C, Chronic Hepatitis B
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study
This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC).
- Trial name
- ROLFH (NCT01831037)
- Testing
- Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
- Where
- 4 sites in United States, Canada
- Sponsor
- University of Arkansas
Healthy Volunteers, Hepatitis B, Chronic
A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R
This phase Ib study included two parts in which Part I was to evaluate the safety and bridge for PK among healthy Chinese subjects and Part II were about study among Chinese chronic hepatitis B virus-infected patients.
- Trial name
- NCT05470829
- Testing
- ZM-H1505R
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Hepatitis B
Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate.
- Trial name
- NCT01599130
- Testing
- Entecavir, Peginterferon alfa-2a
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Hepatitis, Hepatitis B, Chronic
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Conditions
- Hepatitis, Hepatitis B, Chronic, Cirrhosis
- Trial name
- NCT00076336
- Testing
- Telbivudine, Lamivudine
- Where
- 28 sites in United States, Australia and 19 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C, Chronic Hepatitis B
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China
Subjects can be classified into two groups, Group 1 include non-cirrhotic patients, Group 2 include cirrhotic patients. All the patients will be received prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12…
- Trial name
- BDTAF (NCT04997564)
- Testing
- Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University First Hospital
Chronic Hepatitis B
A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
To Evaluate the Tolerability and Pharmacokinetics of LW231 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects .
- Trial name
- NCT06311734
- Testing
- LW231 tablets
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
Chronic Hep B, Chronic Hepatitis b
Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Tune-401 in adult participants with Chronic Hepatitis B.
- Conditions
- Chronic Hep B, Chronic Hepatitis b, Chronic Hepatitis, HBV
- Trial name
- NCT06671093
- Testing
- Tune-401
- Where
- 3 sites in Hong Kong, Moldova and 1 more
- Volunteers
- 36 people
- Sponsor
- Tune Therapeutics, Inc.
Chronic Hepatitis B
Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B
The purpose of this study is to determine the optimal treatment duration of antiviral therapy for chronic hepatitis B.
- Trial name
- NCT00291616
- Testing
- Pegylated Interferon-alpha2a, Thymosin alpha1 & Pegylated Interferon-alpha2a
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Seoul National University Hospital
Hepatitis B, Hepatitis B, Chronic
Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study
The natural history and response to therapy of chronic hepatitis B infection in West Africa are currently poorly understood. In this study, employees of the Cameroon Baptist Convention Health Board (CBCHB) and spouses who are…
- Trial name
- NCT02766933
- Where
- Cameroon
- Volunteers
- 207 people
- Sponsor
- Mayo Clinic
HBV Infection, Chronic Hepatitis b
The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.
This is a multicenter, randomized, open, blank controlled trial ，in order to evaluate the effectiveness and safety of Amibufenamide（TMF） in the treatment of chronic hepatitis B virus infection patients with normal ALT .
- Trial name
- Promote (NCT05797714)
- Testing
- Tenofovir Amibufenamide（TMF）
- Where
- 12 sites in China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Acute on Chronic Liver Failure, Traditional Chinese Medicine
Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment
Background: Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute deterioration in the setting of chronic liver disease associated with high short-term mortality.
- Conditions
- Acute on Chronic Liver Failure, Traditional Chinese Medicine, Hepatitis B
- Trial name
- NCT03577938
- Testing
- Chinese herbal medicine, Control (blank)
- Where
- 15 sites in China
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis B
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
To evaluate the efficacy and safety of combined/uncombined nucleoside (acid) analogues of TQA3810 tablets.
- Trial name
- NCT06566248
- Testing
- TQA3810 tablets+NUC
- Where
- 6 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B, Chronic
Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients
REP 9AC (REP 2055) is a nucleic acid polymer (NAP) with entry activity against hepatitis C virus and entry and post-entry antiviral activity against duck hepatitis B virus (DHBV) infection.
- Trial name
- NCT02646163
- Testing
- REP 2055
- Where
- Bangladesh
- Volunteers
- 8 people
- Sponsor
- Replicor Inc.
Hepatitis B, Chronic
Suboptimal Responders to Adefovir Switching to Entecavir
Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir
- Trial name
- NCT00718887
- Testing
- Entecavir, Adefovir/Entecavir
- Where
- 8 sites in China
- Volunteers
- 228 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis b
A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B
A randomized, double-blind Phase Ib/IIa multicenter trial design was used. All eligible subjects received TQA3605 tablets/placebo plus nucleoside (acid) analogues. A total of 88 subjects were required
- Trial name
- NCT06150014
- Testing
- TQA3605 tablets, Entecavir dispersible tablets, Tenofovir disoproxil fumarate tablet
- Where
- 3 sites in China
- Volunteers
- 88 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis B, Chronic
Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B
Previous studies have shown that there are alterations in the number and affinity of interferon receptors during interferon therapy and that such alterations recover to varying degrees some time after the end of treatment.
- Trial name
- EPCP (NCT05922306)
- Testing
- PEGylated recombinant human interferon alpha-2b injection
- Where
- China
- Volunteers
- 1,084 people
- Sponsor
- Anhui Medical University
Hepatitis B, Chronic, Pregnancy
Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients
This study evaluates generic emtricitabine(FTC) efficacy and safety in Chinese naive pregnant HBsAg positive patients in prevention of HBV vertical transmission.
- Trial name
- NCT02327715
- Testing
- Emtricitabine
- Volunteers
- 200 people
- Sponsor
- Asian-Pacific Alliance of Liver Disease, Beijing